Dallas, TX

Allergy Partners of North Texas Research

Immunologic Deficiency Syndromes

Primary Immunodeficiency Diseases

Peanut Hypersensitivity

Hypersensitivity

CNP-201

Green Cross Corporation

Aimmune Therapeutics

Baxalta

COUR Pharmaceuticals

Grifols

Kedrion Biopharma

condition

allSponsorName

Atlantic Research Group (ARG)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Allergy Partners of North Texas Research | Dallas, TX

Site insights

Work at this site?

Active trials

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Trial sponsors